BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng C, Kar I, Chen CK, Sau C, Woodson S, Serra A, Abboud H. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs 2020;34:879-96. [PMID: 32780300 DOI: 10.1007/s40263-020-00756-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Alroughani R, Inshasi J, Al Khawajah M, Ahmed SF, Al Malik Y, Alkhabouri J, Shatila A, Aljarallah S, Cupler EJ, Qureshi SA, Thakre M, Elhasin H, Ezzat A, Roushdy S. Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review. Mult Scler J Exp Transl Clin 2022;8:20552173221077185. [PMID: 35284088 DOI: 10.1177/20552173221077185] [Reference Citation Analysis]
2 Capuano R, Donnarumma G, Bisecco A, Grimaldi E, Conte M, d'Ambrosio A, Matrone F, Risi M, Borgo RM, Altieri M, Giuliano F, Coppola N, Galdiero M, Tedeschi G, Gallo A. Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab. Ther Adv Neurol Disord 2021;14:17562864211038111. [PMID: 34413902 DOI: 10.1177/17562864211038111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chisari CG, Toscano S, Arena S, Finocchiaro C, Montineri A, Patti F. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurol 2021;21:462. [PMID: 34839814 DOI: 10.1186/s12883-021-02421-3] [Reference Citation Analysis]
4 Colais P, Cascini S, Balducci M, Agabiti N, Davoli M, Fusco D, Calandrini E, Bargagli AM. Impact of the COVID-19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy. Eur J Neurol 2021. [PMID: 33896086 DOI: 10.1111/ene.14879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bhise V, Dhib-Jalbut S. Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. Neurotherapeutics 2021;18:244-51. [PMID: 33533012 DOI: 10.1007/s13311-021-01008-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kasarello K, Mirowska-Guzel D. Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era. Immunotargets Ther 2021;10:237-46. [PMID: 34268256 DOI: 10.2147/ITT.S240890] [Reference Citation Analysis]
7 Kataria S, Tandon M, Melnic V, Sriwastava S. A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies. eNeurologicalSci 2020;21:100287. [PMID: 33163634 DOI: 10.1016/j.ensci.2020.100287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Alnajashi H, Jabbad R. Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic. PLoS One 2020;15:e0241103. [PMID: 33091088 DOI: 10.1371/journal.pone.0241103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Razi O, Tartibian B, Teixeira AM, Zamani N, Govindasamy K, Suzuki K, Laher I, Zouhal H. Thermal dysregulation in patients with multiple sclerosis during SARS-CoV-2 infection. The potential therapeutic role of exercise. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103557] [Reference Citation Analysis]
10 Strober L, Weber E, Lequerica A, Chiaravalloti N. Surviving a global pandemic: The experience of depression, anxiety, and loneliness among individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders 2022;58:103497. [DOI: 10.1016/j.msard.2022.103497] [Reference Citation Analysis]
11 Inshasi J, Alroughani R, Al-Asmi A, Alkhaboury J, Alsalti A, Boshra A, Canibano B, Deleu D, Ahmed SF, Shatila A, Thakre M. Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19. Neurol Ther 2021;:1-17. [PMID: 34155473 DOI: 10.1007/s40120-021-00260-5] [Reference Citation Analysis]
12 Göncüoğlu C, Bayraktar Ekincioğlu A, Tuncer A. The Potential Drug Interactions Between Multiple Sclerosis and COVID-19 Therapies. Turk J Pharm Sci 2021;18:665-6. [PMID: 34978395 DOI: 10.4274/tjps.galenos.2021.92892] [Reference Citation Analysis]
13 Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Reference Citation Analysis]
14 Haham N, Vaknin-Dembinsky A. COVID-19 in Cladribine-treated patient with multiple sclerosis. J Neuroimmunol 2021;359:577690. [PMID: 34390951 DOI: 10.1016/j.jneuroim.2021.577690] [Reference Citation Analysis]
15 Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-or A. Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Front Neurol 2022;13:828616. [DOI: 10.3389/fneur.2022.828616] [Reference Citation Analysis]
16 Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 2021;49:102725. [PMID: 33482590 DOI: 10.1016/j.msard.2020.102725] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
17 Shabani Z. Demyelination as a result of an immune response in patients with COVID-19. Acta Neurol Belg 2021;121:859-66. [PMID: 33934300 DOI: 10.1007/s13760-021-01691-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
18 Diaz de la Fe A, Peláez Suárez AA, Fuentes Campos M, Cabrera Hernández MN, Goncalves CA, Schultz S, Siniscalco D, Robinson-Agramonte MA. SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis. Diseases 2021;9:32. [PMID: 33921878 DOI: 10.3390/diseases9020032] [Reference Citation Analysis]
19 Simões JLB, de Araújo JB, Bagatini MD. Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection. Mol Neurobiol 2021. [PMID: 34247339 DOI: 10.1007/s12035-021-02464-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
21 Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 2021;14:17562864211012835. [PMID: 34035836 DOI: 10.1177/17562864211012835] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 28.0] [Reference Citation Analysis]
22 Khanna A, Jones GB. Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care. Front Digit Health 2021;3:803315. [PMID: 34993505 DOI: 10.3389/fdgth.2021.803315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Iovino A, Olivieri N, Aruta F, Giaquinto E, Ruggiero L, Spina E, Tozza S, Manganelli F, Iodice R. Alemtuzumab in Covid era. Mult Scler Relat Disord 2021;51:102908. [PMID: 33812222 DOI: 10.1016/j.msard.2021.102908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Hatef B, Pirzad Jahromi G, Meftahi GH, Shaygan V, Ghalavand M. Impact of the covid-19 pandemic on the psychological status and cortisol level of multiple sclerosis patients. Neuropsychol Rehabil 2022;:1-24. [PMID: 35507425 DOI: 10.1080/09602011.2022.2069825] [Reference Citation Analysis]
25 Sadeghmousavi S, Rezaei N. COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment. SN Compr Clin Med 2020;:1-6. [PMID: 32895640 DOI: 10.1007/s42399-020-00504-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
26 Abbadessa G, Lavorgna L, Trojsi F, Coppola C, Bonavita S. Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis. Expert Rev Neurother 2021;21:731-43. [PMID: 34278928 DOI: 10.1080/14737175.2021.1957673] [Reference Citation Analysis]
27 Woopen C, Schleußner K, Akgün K, Ziemssen T. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Front Immunol 2021;12:701752. [PMID: 34234787 DOI: 10.3389/fimmu.2021.701752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Abbasi N, Ghadiri F, Moghadasi AN, Azimi A, Navardi S, Heidari H, Karaminia M, Ali Sahraian M. COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103723] [Reference Citation Analysis]
29 Alroughani R, Inshasi J, Al-hashel J, Alkhaboury J, Alsalti A, Al Suwaidi R, Hassino LH, Farouk Ahmed S. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East. Journal of Clinical Neuroscience 2022. [DOI: 10.1016/j.jocn.2022.02.033] [Reference Citation Analysis]
30 Toscano S, Chisari CG, Patti F. Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurol Ther 2021;10:627-49. [PMID: 34625925 DOI: 10.1007/s40120-021-00288-7] [Reference Citation Analysis]
31 Inshasi JS, Alfahad S, Alsaadi T, Hassan A, Zein T, Mifsud VA, Nouri SI, Shakra M, Shatila AO, Szolics M, Thakre M, Kumar A, Boshra A. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates. Neurol Ther 2021. [PMID: 33891277 DOI: 10.1007/s40120-021-00243-6] [Reference Citation Analysis]
32 Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. J Neuroimmunol 2021;356:577599. [PMID: 34000472 DOI: 10.1016/j.jneuroim.2021.577599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
33 Dewanjee S, Vallamkondu J, Kalra RS, Puvvada N, Kandimalla R, Reddy PH. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic. Mol Neurobiol 2021. [PMID: 34169443 DOI: 10.1007/s12035-021-02450-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. Neurol Ther 2022;11:571-95. [PMID: 35318617 DOI: 10.1007/s40120-022-00339-7] [Reference Citation Analysis]
35 Capone F, Motolese F, Luce T, Rossi M, Magliozzi A, Di Lazzaro V. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult Scler Relat Disord 2021;48:102734. [PMID: 33429305 DOI: 10.1016/j.msard.2020.102734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
36 Fronza M, Lorefice L, Frau J, Cocco E. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. Drug Des Devel Ther 2021;15:1993-2004. [PMID: 34007159 DOI: 10.2147/DDDT.S240861] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Boyko AN, Sivertseva SA, Chemakina DS, Spirin NN, Bykova OV, Guseva ME. [Vaccination and multiple sclerosis at the present stage]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:44-8. [PMID: 34387445 DOI: 10.17116/jnevro202112107244] [Reference Citation Analysis]
38 Etemadifar M, Sedaghat N, Nouri H, Lotfi N, Chitsaz A, Khorvash R, Zolfaghari H, Ghasemi Movaghar A, Pourabbas M, Salari M. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. Mult Scler Relat Disord 2021;57:103417. [PMID: 34875487 DOI: 10.1016/j.msard.2021.103417] [Reference Citation Analysis]
39 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
40 Solmaz I, Anlar B. Immunization in multiple sclerosis and other childhood immune-mediated disorders of the central nervous system: A review of the literature. Eur J Paediatr Neurol 2021;33:125-34. [PMID: 34214824 DOI: 10.1016/j.ejpn.2021.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Khayat-Khoei M, Bhattacharyya S, Katz J, Harrison D, Tauhid S, Bruso P, Houtchens MK, Edwards KR, Bakshi R. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 2021. [PMID: 34480607 DOI: 10.1007/s00415-021-10780-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Mult Scler 2022;:13524585211069068. [PMID: 35196927 DOI: 10.1177/13524585211069068] [Reference Citation Analysis]
43 Shi Y, Guo M, Yang W, Liu S, Zhu B, Yang L, Yang C, Liu C. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases? Expert Rev Vaccines 2021;20:375-83. [PMID: 33787439 DOI: 10.1080/14760584.2021.1911653] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Ziello A, Scavone C, Di Battista ME, Salvatore S, Di Giulio Cesare D, Moreggia O, Allegorico L, Sagnelli A, Barbato S, Manzo V, Capuano A, Maniscalco GT. Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. Brain Sci 2021;11:890. [PMID: 34356125 DOI: 10.3390/brainsci11070890] [Reference Citation Analysis]
45 Xu Y, Cao Y, Ma Y, Zhao Y, Jiang H, Lu J, Zhao C, Quan C. COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style. Front Neurol 2021;12:717111. [PMID: 34421811 DOI: 10.3389/fneur.2021.717111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Galati A, Brown ES, Bove R, Vaidya A, Gelfand J. Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist. J Neurol Sci 2021;430:120004. [PMID: 34598056 DOI: 10.1016/j.jns.2021.120004] [Reference Citation Analysis]